KDM5A and breast cancer: Moreover, evidence presented here suggests that the demethylase activity of KDM5A is indeed required for the development of drug tolerance to two different targeted therapies, a small molecule and a monoclonal antibody targeting members of the epidermal growth factor receptor family in lung and breast cancer, respectively (Figure 6).